According to a definitive agreement between Indivior PLC and Opiant Pharmaceuticals, Inc., which the two companies announced today, Indivior will buy Opiant for an upfront payment of $20.00 per share in cash (roughly $145 million total), plus up to $8.00 per share in contingent value rights (“CVRs”) that could become […]
Featured News
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
Creating a New Paradigm in Precision Medicine for The Company Fulgent Pharma Holdings, Inc., an independent clinical-stage, therapeutics development company focused on the development of cutting-edge cancer treatments, has been acquired by Fulgent Genetics, Inc., a technology-based genetic testing business focused on transforming patient care in oncology, infectious and rare […]
Karyopharm and Menarini Group announce orphan drug designation by the European Commission for selinexor for the treatment of myelofibrosis
The Menarini Group, a prominent privately held international pharmaceutical company, and Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted selinexor orphan Medicinal Product Designation. It is intended to be used to treat myelofibrosis (MF). In May 2022, the […]
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
CSL Enters Licensing Agreement with Arcturus Therapeutics : Today, CSL Limited reports that its subsidiary, CSL Seqirus, has collaborated and licenced its late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology to Arcturus Therapeutics Holdings Inc (or “Arcturus Therapeutics”). Future mRNA vaccines are being created by Arcturus Therapeutics. It has created a […]
Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials
Electronic Data Capture in Clinical Trials Boehringer Ingelheim and Medidata, a Dassault Systems firm, today announced a five-year extension of their partnership in the broader field of electronic data collection. The new arrangement includes myMedidata, Medidata’s portfolio of cutting-edge patient-facing technologies aimed at boosting patient centricity and diversity in decentralised […]
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
INO-4800 was going to be developed as a COVID-19 heterologous booster vaccine, but INOVIO, a biotechnology company specialising in the development and commercialization of DNA medicines to help treat and prevent infectious diseases, cancer, and diseases linked to HPV, has announced today that it has stopped doing so. The choice […]
Evidation Launches FluSmart, A Direct-to-Person Digital Flu Monitoring Program, To Better Understand Flu in Everyday Life
In order to understand the flu at its earliest stages, people, researchers, and public and private organisations are brought together in FluSmart, a digital flu monitoring programme that was recently introduced by Evidation, the company that connects directly with people to measure health in everyday life. FluSmart, a nationwide programme […]
Adventist HealthCare Rehabilitation Ranked Among Best in Nation and No. 1 in the Region
Adventist HealthCare Rehabilitation Ranked Among Best in Nation and No. 1 in the Region : Recently, Newsweek magazine and Statista Inc., a top global provider of data and rankings, selected Adventist HealthCare Rehabilitation as one of the top inpatient rehabilitation facilities (IRF) in the United States and first in the […]
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
In order to provide its investigational positron emission tomography (PET) imaging radiotracers, TLX250-CDx (Zr-DFO-girentuximab) and [18F]-FLac (F-3-fluoro-2-hydroxypropionate) for use in third-party clinical research and development activities, Telix Pharmaceuticals Limited has announced a collaborative development and reseller agreement with GE Healthcare. These cutting-edge tracers have the potential to reveal crucial details […]
To improve the patient experience, Veristat joins the Decentralized Trials & Research Alliance (DTRA).
To improve the patient experience, Veristat joins the Decentralized Trials & Research Alliance (DTRA). Veristat announces that it has joined an alliance of more than 120 healthcare and life science companies whose goal is to hasten the widespread implementation of patient-centered, decentralised clinical trials. Healthcare providers, government agencies, patient advocacy […]
